Press Releases April 22, 2026 07:00 AM

Lantronix to Report Fiscal 2026 Third Quarter Results on May 6, 2026

Lantronix schedules release of fiscal Q3 2026 financial results with investor webcast

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
LTRX

Lantronix Inc., a Nasdaq-listed leader in Edge AI and Industrial IoT solutions, announced it will report its fiscal third quarter 2026 financial results on May 6, 2026, followed by a management-hosted conference call and webcast. The company provides intelligent computing and secure connectivity solutions for mission-critical applications across sectors such as smart cities, enterprise IT, and unmanned systems.

Lantronix to Report Fiscal 2026 Third Quarter Results on May 6, 2026
LTRX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Lantronix serves high-growth markets including smart cities, enterprise IT, and commercial/defense unmanned systems.
  • The company enables digital transformation through hardware, software, and services focused on edge AI and Industrial IoT.
  • Fiscal Q3 2026 results and investor webcast scheduled for May 6, 2026, signaling transparency and engagement with investors.

IRVINE, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Lantronix Inc. (the “Company”) (NASDAQ: LTRX), a global provider of Edge AI and Industrial IoT solutions that power NDAA-compliant unmanned systems, critical infrastructure and resilient enterprise networks, today announced it will release financial results from its fiscal 2026 third quarter, ended March 31, 2026, after the close of the market on Wednesday, May 6, 2026.

Management will host an investor conference call and audio webcast at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on May 6, 2026. To access the live conference call, investors should dial 1-844-802-2442 (U.S.) or 1-412-317-5135 (international) and indicate they are participating in the Lantronix fiscal 2026 third-quarter call. The webcast will be available simultaneously via the investor relations section of the Company’s website.

Investors can access a conference call replay starting at approximately 4:00 p.m. Pacific Time on May 6, 2026, on the Lantronix website. A telephonic replay will also be available through May 13, 2026, by dialing 1-855-669-9658 (U.S. & Canada Toll-Free) or 1-412-317-0088 (international) and entering passcode 7909343.

About Lantronix

Lantronix Inc. (Nasdaq: LTRX) is a global leader in Edge AI and Industrial IoT solutions, delivering intelligent computing, secure connectivity and remote management for mission-critical applications. Serving high-growth markets, including smart cities, enterprise IT and commercial and defense unmanned systems, Lantronix enables customers to optimize operations and accelerate digital transformation. Its comprehensive portfolio of hardware, software and services powers applications from secure video surveillance and intelligent utility infrastructure to resilient out-of-band network management. By bringing intelligence to the network edge, Lantronix helps organizations achieve efficiency, security and a competitive edge in today’s AI-driven world.

For more information, visit the Lantronix website.

© 2026 Lantronix Inc. All rights reserved. Lantronix is a registered trademark. Other trademarks and trade names are those of their respective owners.

Lantronix Media Contact:        
[email protected]

Lantronix Analyst and Investor Contact:        
[email protected]


Risks

  • Financial performance risks inherent in reporting quarterly earnings, which may affect investor sentiment.
  • Dependence on sectors like smart cities and defense, which may face regulatory or budgetary changes.
  • Competitive pressures in the IoT and Edge AI markets could impact growth and margins.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026